JNJ240726C146000
- 7.90
- 0.000.00%
Johnson & Johnson Newsroom
J&J Talc Bankruptcy Plan Appeal Denied
'Never Going to Be the Same': How Nvidia Is Trying to Revolutionize Healthcare
Johnson & Johnson | 10-Q: Quarterly report
AC Immune Stock Climbs 7% on FDA Fast Track Status for Alzheimer's Drug
Here's What To Do Next After the Big Stock Market Slide
Dow's 275-Point Rally Led By Gains In IBM, Salesforce Stocks
Looking Into Johnson & Johnson's Recent Short Interest
AbbVie Raises Outlook as New Immunology Drugs Offset Humira Impact
Newly-Listed Psoriasis Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Bio-Thera Biosimilar to J&J's Stelara Under FDA Review
Check Out What Whales Are Doing With JNJ
Johnson & Johnson (JNJ) Is Attracting Investor Attention: Here Is What You Should Know
Health Care Stocks Steady With Broader Market -- Health Care Roundup
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Maintain for one month! Johnson & Johnson (JNJ.US) submits new indications for anti-depressant nasal sprays.
On July 22, Johnson & Johnson (JNJ.US) announced the submission of a supplemental New Drug Application (sNDA) to the US FDA.
Time for Healthcare ETFs?
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Alvotech Launches First Biosimilar of J&J's Stelara in Europe
Sector Update: Health Care Stocks Rise in Monday's Premarket Hours